Results 181 to 190 of about 881,201 (350)

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Venoarterial Membrane Oxygenation in Cardiogenic Shock Complicated from an Acute Myocardial Infarction: An Overview and Comprehensive Meta-Analysis

open access: yesBiomedicines
Background: Cardiogenic shock remains a significant cause of mortality in patients with acute coronary syndrome, despite early interventions, such as coronary revascularization.
Kiarash Sassani   +7 more
doaj   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early ...
Antoni Bayes‐Genis   +13 more
wiley   +1 more source

201 Cardiogenic Shock and Multiple-Organ Failure [PDF]

open access: bronze, 1993
N Oohama   +3 more
openalex   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

open access: yesEuropean Journal of Heart Failure, EarlyView.
Improving clinical translation of mitoprotective therapies. 31P MRI, phosphorus‐31 magnetic resonance imaging; hiPSC‐CM, human‐induced pluripotent stem cell‐derived cardiomyocyte; IHD, ischaemic heart disease. Abstract Acute myocardial infarction (MI) remains a major cause of death and disability worldwide.
Melanie Paillard   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy